Cullinan Therapeutics targets rheumatoid arthritis with CD19 T cell engager

Cullinan Therapeutics targets rheumatoid arthritis with CD19 T cell engager
Cullinan moves on autoimmune therapy

Cullinan Therapeutics is progressing the development of its CD19-directed T cell engager, CLN-978, as a potential treatment for autoimmune diseases including rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus.

Chief Medical Officer Jeff Jones recently outlined the therapeutic focus in a video created together with the Global Healthy Living Foundation. The initiative positions CLN-978 within a growing field of targeted therapies aimed at immune system modulation for chronic conditions. Additional details can be found via Cullinan Therapeutics resources.

Cullinan Therapeutics recently announced its Q2 2026 financial results and provided updates on key milestones for its T cell engager pipeline, including CLN-978, as detailed in company statements. The company has also engaged in industry events, supporting diversity by sponsoring LGBTQIA biotech professionals at OUTbio Boston. These efforts reflect Cullinan's ongoing activity in both clinical development and community engagement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.